Table 3.
Comparison of MSAs/MAAs between IIM patients with RP-ILD and C-ILD.
| Variables | RP-ILD n = 82 | C-ILD n = 125 | P-value |
|---|---|---|---|
| MYOSITIS-SPECIFIC ANTIBODIES | |||
| Anti-synthetase antibodies (+), no. (%) | 35 (42.7) | 71 (56.8) | 0.047* |
| Anti-Jo-1, no. (%) | 11 (13.4) | 40 (32.0) | 0.002* |
| Anti-MDA5, no. (%) | 32 (39.0) | 15 (12.0) | 0.000* |
| Anti-Mi-2, no. (%) | 2 (2.4) | 3 (2.4) | 1.000 |
| Anti-TIF1-γ, no. (%) | 3 (3.7) | 4 (3.2) | 1.000 |
| Anti-NXP2, no. (%) | 2 (2.4) | 4 (3.2) | 1.000 |
| Anti-SAE, no. (%) | 2 (2.4) | 3 (2.4) | 1.000 |
| MYOSITIS-ASSOCIATED ANTIBODIES | |||
| Anti-Ro-52, no. (%) | 48 (58.5) | 51 (40.8) | 0.012* |
| Anti-PM/Scl-75/100, no. (%) | 8 (9.8) | 15 (12.0) | 0.615 |
| Anti-Ku, no. (%) | 3 (3.7) | 7 (5.6) | 0.743 |
*
< 0.05. IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; RP-ILD, rapidly progressive ILD; C-ILD, Chronic ILD. ARS include EJ, OJ, PL-7, PL-12, KS. ARS, aminoacyl-tRNA synthetase; MDA5, melanoma differentiation-associated 5; TIF-1γ, translation initiation factor-1a; NXP2, nuclear matrix protein 2; SAE, small ubiquitin-like modifier enzyme; PM/Scl, polymyositis/scleroderma.